Estrogenotherapy: For whom, why and how?;L'œstrogénothérapie substitutive: Pour qui, pourquoi, comment?

Revue Medicale de Bruxelles

Volumn 23, Issue 4, 2002, Pages

  Rozenberg, S ^a   Neusy, S ^a   Barudy, J ^a   Fellemans, C ^a   Jahjah, L ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

HRT; Menopause

Indexed keywords

ESTROGEN; GESTAGEN;

ATHEROMATOSIS; ATHEROSCLEROSIS; BLEEDING; BONE DENSITY; BONE MASS; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; ESTROGEN THERAPY; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; ORAL CONTRACEPTION; PATIENT COMPLIANCE; SYMPTOM; THROMBOSIS; BREAST TUMOR; CARDIOVASCULAR DISEASE; CLIMACTERIUM; MENSTRUAL CYCLE; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 11244296737     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Greendale GA, Lee NP, Arriola E: The menopause. Lancet 1999; 353: 571-80
2. Burger HG, Dudley EC, Robertson DM, Dennerstein L: Hormonal changes in the menopause transition. Recent Prog Horm Res 2002; 57: 257-75
3. Lethaby AE, Cooke I, Rees M: Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD002126
4. Cordozo L, Bachmann G, McClish D et al: Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998; 92: 722-7
5. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H: Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002; 77 (Suppl 4): 42-8
6. Bachmann GA: The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 2002; 77 (Suppl 4): 72-6
7. Miller KK: Androgen Deficiency in Women. J Clin Endocrinol Metab 2001; 86: 2395-401
8. Birkhäuser M: Depression, menopause and estrogens: is there a correlation? Maturitas 2002; 41 (Suppl 1): 3-8
9. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11
10. Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. Ann Intern Med 2001; 135: 1-8
11. Hulley S, Grady D, Bush T et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13
12. Writing Group for the Women's Health Initiative Investigators: Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33
13. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-9
14. Michaelsson K, Baron JA, Farahmand BY et al: Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316: 1858-63
15. Prestwood KM, Thompson DL, Kenny AM, Seibel MJ, Pilbeam CC, Raisz LG: 1999 Low Dose Estrogen and Calcium Have an Additive Effect on Bone Resorption in Older Women. J Clin Endocrinol Metab 1999; 84: 179-83
16. Lees B, Stevenson JC: The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int 2001; 12: 251-8
17. Heikkinen J, Vaheri R, Kainulainen P, Timonen U: Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int 2000; 11: 929-37
18. Rozenberg S: Clinical evidence supporting the rationale for constant estrogen, intermittent progestogen hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2001; 94: 86-91
19. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S: Use of low potency estrogens does not reduce the risk of hip fracture. Bone 2002; 30: 613-8
20. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047-59
21. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Estrogen-progestin replacement and risk of breast cancer. JAMA 2000; 284: 691-4